Merck & Co., Inc. news

   Watch this stock
Showing stories 21 - 30 of about 162   

Articles published

MRK 58.53 -0.01 (-0.01%)
price chart
Active Stocks Under Consideration: SunEdison, Inc. (NYSE:SUNE), Merck & Co ...
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection ...
Short Interest Update of Merck & Company, Inc. (NYSE:MRK)
Merck & Company, Inc. (NYSE:MRK) reported a rise of 1.8% or 579,684 shares in its short interest. The short figure came in at 1.2% of the total floats.
Can Merck & Company, Inc. (NYSE:MRK) Meet Analyst Targets?
In the most recent quarter, Merck & Company, Inc. (NYSE:MRK) reported an earnings surprise of 13.33% when the firm last announced their results for the period ending on 2015-03-31.
Earnings Focus: Merck & Company, Inc. (NYSE:MRK)  Markets Daily
Morning Momentum: Merck & Co. Inc. (MRK), FireEye, Inc. (FEYE), Carnival ...  WallStreet Scope
Stock to Follow: Merck & Co Inc (NYSE:MRK)
[Business Wire] Merck & Co Inc (NYSE:MRK)(TREND ANALYSIS) known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for ...
Merck Announces European Medicines Agency Acceptance of Marketing ...  Business Wire (press release)
One Put, One Call Option To Know About for Merck & Co.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc (Symbol: MRK). So this week we highlight one interesting put contract, and one interesting call contract, from the ...
Analyst Rating Update on Merck & Company, Inc.
Merck & Company (NYSE:MRK) has received a buy rating for the short term, according to the latest rank of 2 from research firm, Zacks.
Merck & Co. Raised to Strong-Buy at Vetr Inc. (MRK)  The Legacy
Market Update: Merck & Co Inc (NYSE:MRK) - Merck Marks 30-Year Milestone in ...
Merck & Co Inc (NYSE:MRK) [Business Wire] - Merck , known as MSD outside the United States and Canada, announced today that the company's commitment to HIV and AIDS, which started with a research and development program initiated in the ...
Merck Marks 30-Year Milestone in Commitment to Innovation and Care in HIV/AIDS  MarketWatch
Active Stocks News Alert: Merck & Co., Inc. (NYSE:MRK), Rayonier Inc. (NYSE ...
Merck & Co., declared results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND (fosaprepitant dimeglumine) for Injection, Merck's substance P/neurokinin (NK-1) receptor antagonist, in combination with other anti-vomiting ...
Merck's Keytruda cleared in Europe for advanced melanoma (MRK)
As expected, the European Commission approves Merck's (MRK -0.6%) Keytruda (pembrolizumab) for the treatment of adult patients with advanced (unresectable or metastatic) melanoma.
Merck & Co. Inc. (NYSE:MRK) Please To Announces European Commission ...  StreetWise Report
Merck's Anti-PD-1 Therapy Melanoma Drug Gets EU Nod - Analyst Blog  Nasdaq
Just Perfect: Compensatory Patent Damages in Apotex Inc v Merck & Co, Inc
The Federal Court of Appeal has decided that when computing compensatory damages for patent infringement, the availability of a non-infringing alternative is now a legally relevant consideration that can reduce the lost profits an infringer is liable ...